Low dose vincristine-induced severe polyneuropathy in a hodgkin lymphoma patient: A case report (Vincristine-induced Severe Polyneuropathy)

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 10, 2009, Pages 787-789

  Cil, Timucin ^a   Altintas, Abdullah ^b   Tamam, Yusuf ^a   Battaloǧlu, Esra ^c   Isikdogan, Abdurrahman ^a  

^a DICLE UNIVERSITY   (Turkey)

^b Internal Medicine   (Turkey)

^c BOGAZICI UNIVERSITY   (Turkey)

Author keywords

Charcot Marie Tooth Type 1A; Neuropathy; Vincristine

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CASE REPORT; ELECTROMYOGRAPHY; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; PHYSICAL EXAMINATION; POLYNEUROPATHY; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHARCOT-MARIE-TOOTH DISEASE; FEMALE; HODGKIN DISEASE; HUMANS; POLYNEUROPATHIES; PROTEINS; VINCRISTINE;

EID: 70349823608     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b530ad     Document Type: Article

References (13)

1. Bromberg MB. Peripheral neurotoxic disorders. Clin Neurobehav Toxicol. 2000;18:681-689.
2. Casey EB, Fullerton PM, Jelli.e AW. Vincristine neurotoxicity: A clinical and electrophysiological study of eighteen patients. Clin Sci. 1970;38:23-24.
3. Casey EB, Jellife AM, Le Quesne PM, et al. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96:69-86.
4. Hildebrandt G, Holler E, Woenkhaus M, et al. Acute deterioration of Charcot-Marie Tooth disease IA (CMT IA) following 2mg of vincristine chemotherapy. Ann Oncol. 2000;11:743-747.
5. Igarashi M, Thompson EI, Rivera GK. Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol. 1995;25: 113-116.
6. Bird TD. Hereditary motor-sensory neuropathies. Charcot- Marie-Tooth syndrome. Neurol Clin. 1989;7:9-23.
7. Chauvenetallen R, Vandana S, Selsky C, et al. Vincristineinduced neuropathy as the initial presentation of CMT disease in acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Hametol Oncol. 2003;25:316-320.
8. Ionasescu VK. Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve. 1995; 18:267-275.
9. Lupski JR, Montes de Oca-Luna R, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type IA. Cell. 1991;66:219-232.
10. Nicholson G. Myelin gene dosage and mutation in the hereditary motor and sensory neuropathies: A review. J Neurol Neurosurg Psychiatry. 1995;58:523-525.
11. Weimer LH, Podwall D. Medication-induced exacerbation of in CMT Disease. J Neurol Sci. 2006;242:47-54.
12. Hogan-Dann CM, Fellmeth WG, McGuire SA, et al. Poly-neuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA. 1984;252: 2862-2863.
13. Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol. 2001; 115:323-325.